Mahacef-Plus Tablet is a combination antibiotic formulation containing Cefixime 200 mg and Ofloxacin 200 mg, designed for the treatment of a broad spectrum of bacterial infections. Cefixime, a third-generation cephalosporin, exerts its bactericidal effect by inhibiting bacterial cell wall synthesis, effective against various Gram-positive and Gram-negative organisms. Ofloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial replication and transcription. The synergistic action of these two agents enhances antimicrobial efficacy, making Mahacef-Plus suitable for managing complicated urinary tract infections, respiratory tract infections, otitis media, gonorrhea, and certain skin and soft tissue infections caused by susceptible strains. This combination is particularly useful in cases where mixed infections or resistant pathogens are suspected. Mahacef-Plus should be administered as prescribed by a healthcare professional, with dosage adjusted according to the severity of infection and patient-specific factors such as renal function. Caution is advised in patients with a history of hypersensitivity to cephalosporins or fluoroquinolones. Common side effects may include gastrointestinal disturbances, headache, and dizziness. Proper adherence to the prescribed regimen is essential to prevent the development of antibiotic resistance.